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Abstract
The epithelial to mesenchymal transition (EMT) contributes to tumor invasion and metastasis in a variety of cancer types. In
human breast cancer, gene expression studies have determined that basal-B/claudin-low and metaplastic cancers exhibit
EMT-related characteristics, but the molecular mechanisms underlying this observation are unknown. As the family of miR-
200 microRNAs has been shown to regulate EMT in normal tissues and cancer, here we evaluated whether the expression of
the miR-200 family (miR-200f) and their epigenetic state correlate with EMT features in human breast carcinomas. We
analyzed by qRT-PCR the expression of miR-200f members and various EMT-transcriptional inducers in a series of 70 breast
cancers comprising an array of phenotypic subtypes: estrogen receptor positive (ER+), HER2 positive (HER2+), and triple
negative (TN), including a subset of metaplastic breast carcinomas (MBCs) with sarcomatous (homologous or heterologous)
differentiation. No MBCs with squamous differentiation were included. The DNA methylation status of miR-200f loci in tumor
samples were inspected using Sequenom MassArrayH MALDI-TOF platform. We also used two non-tumorigenic breast basal
cell lines that spontaneously undergo EMT to study the modulation of miR-200f expression during EMT in vitro. We
demonstrate that miR-200f is strongly decreased in MBCs compared with other cancer types. TN and HER2+ breast cancers
also exhibited lower miR-200f expression than ER+ tumors. Significantly, the decreased miR-200f expression found in MBCs
is accompanied by an increase in the expression levels of EMT-transcriptional inducers, and hypermethylation of the miR-
200c-141 locus. Similar to tumor samples, we demonstrated that downregulation of miR-200f and hypermethylation of the
miR-200c-141 locus, together with upregulation of EMT-transcriptional inducers also occur in an in vitro cellular model of
spontaneous EMT. Thus, the expression and methylation status of miR-200f could be used as hypothetical biomarkers to
assess the occurrence of EMT in breast cancer.
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Introduction
Breast cancer constitutes a heterogeneous disease encompassing
a large variety of entities with different clinical features. During the
last decade gene expression profiling studies have established
a molecular taxonomy of breast cancer defining four intrinsic
molecular groups with clinical relevance: luminal A, luminal B,
HER2+, and basal-like [1,2,3]. Luminal subtypes are defined by
a gene expression signature partially resembling that of the luminal
epithelial layer of the mammary gland, with positive expression of
estrogen (ER) and/or progesterone (PR) receptors. HER2 tumors
exhibit overexpression of the HER2 receptor and neighboring
genes on 17q12–21 amplicon. Basal-like tumors are defined by the
expression of basal/myoepithelial markers and generally lack the
expression of ER, PR and HER2. Importantly, this molecular
classification predicts treatment response and prognosis: Tumors
classified into the basal-like and HER2 groups exhibit more
aggressive clinical behavior compared to carcinomas with luminal
gene expression signatures (reviewed in [4]).
Transcriptomic studies of breast cancer cell lines have
corroborated this molecular classification and identified two
clusters within the basal group: basal A, exhibiting basal/epithelial
features, and basal B, composed by a subset of mesenchymal-like
cell lines with enhanced invasive properties [5,6,7]. Similarly,
recent studies in human breast cancers described a novel
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Figure 1. Expression profile of miR-200f and EMT-transcriptional inducers in breast tumors. The expression levels of miR-200 family
members (A) and EMT-transcriptional inducers (B) were quantified by qRT-PCR in 70 breast cancer samples. Data are depicted as box-and-whisker
plots. Adjusted p-values are shown where significant differences were found (Wilcoxon rank-sum test). ER+ (estrogen receptor positive tumors),
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molecular subset of tumors within the basal-like phenotype, named
claudin-low [8]. These claudin-low tumors resemble basal B breast
cancer cell lines and are characterized by the enrichment for stem
cell-like features and gene expression changes associated to EMT
[8,9,10,11].
EMT and the reverse process MET (mesenchymal-epithelial
transition) are fundamental processes in developmental morpho-
genesis and have been proposed to play a key role in cancer
development [12,13]. Epithelial cells undergoing EMT lose cell-
cell interactions and other epithelial traits while acquiring
a migratory and invasive phenotype. This has led to the notion
that EMT is an important event for tumor invasion and metastasis.
Moreover, EMT appears to be associated with a stem cell-like
phenotype that would endow tumor cells with the ability to self-
renew, a necessary property to initiate colonization at distant
metastasis [5,13,14,15]. However, the precise occurrence of EMT
in human cancer is still a matter of intense debate [16], due to the
transient nature of the process and the possibility that it might only
occur in specific tumor areas where cancer cells invade. In human
breast cancer, we have previously reported that basal-like tumors
and metaplastic breast carcinomas (MBCs) might undergo EMT-
like processes [17]. MBCs, a specific subset of triple-negative
tumors (TN, HER2–/ER–/PR–), are characterized by the
presence of adenocarcinoma and metaplastic elements with
squamous, sarcomatous or heterologous differentiation, and
a clonal origin of both components has been suggested [18].
Therefore, MBCs represent extreme examples of phenotypic
plasticity that may be related to the high aggressiveness and the
characteristic metastatic spreading of these tumors. Indeed,
MBCs, originally classified as basal-like tumors [19], show a strong
claudin-low/EMT-enriched phenotype [17,20].
Functional E-cadherin loss is a hallmark of EMT. Several E-
cadherin repressors, such as SNAI1, SNAI2, ZEB1 and ZEB2,
function as EMT-transcriptional inducers [21] and their over-
expression in cancer cells associate to EMT features and generally
aggressive tumors [22]. However, these transcription repressors
are not the only EMT drivers. In the past few years several studies
reported on the involvement of microRNAs (miRNAs) in
controlling EMT [23,24,25]. miRNAs are small non-coding
RNAs (,23 nt) that silence gene expression by pairing to the
39UTR of target mRNAs to direct their posttranscriptional
repression [26]. Members of the miR-200 family (miR-200f) have
been shown to be major regulators of EMT through the targeted
silencing of the EMT-transcriptional inducers ZEB1 and ZEB2,
which in turn transcriptionally repress miR-200f in a double-
negative feedback loop [27,28]. In addition, miR-200f opposes
EMT by directly targeting genes involved in motility and invasion
[29,30]. Therefore, expression of miR-200f in normal and cancer
cells promotes the maintenance of an epithelial phenotype [31].
The five members of the miR-200f are grouped in two
independent transcriptional units: a) miR-200b, miR-200a and
miR-429 are clustered in an intergenic region of chromosome 1;
and b) miR-200c and miR-141 are located on chromosome 12,
within the intron of a noncoding RNA. Recent studies have shown
that both clusters are subject to epigenetic regulation in cancer and
normal tissue [32,33,34,35]. Indeed, epigenetic regulation appears
to be a dynamic process affecting miR-200f expression to
modulate EMT-MET [36].
Since miR-200f is an important modulator of EMT, a compre-
hensive study on the expression of miR-200f members in the broad
spectrum of breast cancer tumor types is warranted. Here we have
analyzed the expression pattern of miR-200f members and their
DNA methylation status in a series of breast tumors comprising
ER+, HER2+, TN, and MBC types, as well as in a panel of breast
cancer cell lines, and an in vitro model of spontaneous EMT.
Methods
Ethics Statement
This study was performed following standard ethical procedures
of the Spanish regulation (Ley de Investigacio´n Orga´nica
Biome´dica, 14 July 2007) and was approved by the ethics
committee of the Hospital Virgen del Rocı´o de Sevilla and the
Fundacio´n Pu´blica Andaluza para la Gestio´n de la Investigacio´n
en Salud de Sevilla (FISEVI), Spain. Written informed consent has
been obtained and all clinical investigation has been conducted
according to the principles expressed in the Declaration of
Helsinki.
Human Tumors
A series of 70 formalin-fixed paraffin-embedded (FFPE) human
breast tumors were obtained from the archives of the Department
of Pathology of the Hospital Universitario Virgen del Rocı´o,
Sevilla, Spain. The series included 16 luminal breast carcinomas
(ER+/PR+/HER22), 21 HER2 carcinomas (HER2+/ER2/
PR2), 26 TN tumors (HER22/ER2/PR2), and 7 MBCs
(which are triple negative as well). Clinical data of the tumor
sample are provided in Table S1. Carefully examination of the
H&E-stained sections was carried out by pathologists (JP, MAL,
BV) confirming the diagnosis on the basis of histological criteria.
Immunohistochemistry was carried out on tissue microarray
sections using the Envision method (Dako, CA, USA) and primary
antibodies for E-cadherin (Zymed, CA, US) and Vimentin
(Novocastra, UK). Immunohistochemical staining was evaluated
by pathologists (JP, MAL, BV).
Cell Lines
Six breast cancer cell lines with different phenotypes - MCF7,
T47D, BT-474, SKBR3, MDA-MB-231 and BT549 - were
obtained from the American Tissue Culture Collection (ATCC)
and cultured according to ATCC’s recommendation. The non-
tumorigenic basal cell lines MCF12A (from ATCC) and Myo1089
[37](kindly provided by Dr Michael Allen and Dr Louise Jones,
Queen Mary’s University London) were grown in DMEM:F12
medium supplemented with 5% horse serum (Invitrogen, Life
Technologies, Paisley, UK), 20 ng/ml EGF (PreproTech, London,
UK), 500 ng/ml hydrocortisone (Sigma, Poole, UK), 100 ng/ml
cholera toxin (Sigma), and 10 mg/ml insulin (Sigma). These non-
tumorigenic basal cell lines were utilized as models for spontane-
ous EMT as previously reported [38]. The epithelial and
mesenchymal-like subpopulations within these cell lines were
purified by FACS sorting using EpCAM and CD49f surface
markers as described before [38].
Nucleic Acid Isolation
Total RNA was extracted in triplicate from 90% confluent cells
using mirVana miRNA isolation kit (Ambion, Austin, TX, USA).
HER2+ (HER2-positive tumors), TN (triple negative; ER2, PR2, HER22), MBC (metaplastic breast carcinomas). (C) Upper heatmap represents Pearson
coefficient (R) correlation values between the expression of EMT-transcriptional inducers and miR200f members. Bottom heatmap depicts the level of
statistical significance (P) of the correlations.
doi:10.1371/journal.pone.0047709.g001
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For FFPE tumors samples, RNA was isolated from selected areas
containing .70% tumor cells. After deparaffinization, the tissue
was homogenized for 2 minutes in lysis buffer, using an Ultra-
turrax (T10 Basic, IKA, Germany) according to the manufac-
turer’s protocol (Recover AllTM total nucleic acid isolation kit,
Ambion). DNA from FFPE tumors samples and cell lines were
prepared using QIAGEN QIAamp TM DNA FFPE Tissue Kit and
QIAampH DNA Mini Kit respectively, according to the
manufacturer’s instructions (QIAGEN). The quantity and quality
of RNA and DNA were measured with the NanoDrop ND-100
Spectrophotometer (Thermo Scientific, USA).
Real-Time qRT-PCR
miRNA expression was measured by qRT-PCR using custom-
ized Taqman miRNA Arrays (Applied Biosystems). In brief,
700 ng total RNA was subjected to reverse transcription using the
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosys-
tems) according to the manufacturer’s instructions. MegaplexTM
RT primers (Human Pool A) were used for reverse transcription
and thermal-cycling was performed over 40 cycles (16uC, 2 min;
42uC 1 min; 50uC 1 min). qRT-PCR reactions were performed
on an Applied Biosystems 7900HT Fast Real Time PCR System
(95uC 10 min, 40 cycles of 95uC 15 sec and 60uC 60 sec). RNU48
was selected as endogenous control for normalization due to its
consistent expression among all samples.
For gene expression analysis we used 800 ng of total RNA for
the reverse transcription using the High Capacity RNA to cDNA
kit (Applied Biosystems) according to the manufacturer’s protocol.
qRT-PCR reactions were performed using Taqman Array Cards
(Applied Biosystems) including probes for: SNAI1, SNAI2, ZEB1
and ZEB2. 18S was used as endogenous control to normalize
variations in the quantities of input cDNA. Applied Biosystems
7900HT Fast Real Time PCR System was used with the following
PCR conditions: 50uC 2 min; 94.5uC 10 min; 40 cycles of melting
97uC 30 sec and annealing 59.7uC 1 min.
Relative mRNA and miRNA expression levels were calculated
by the formula 22DDCt using SDS software (Applied Biosystems).
DNA Methylation Analysis
1 mg of genomic DNA was used for sodium bisulfite conversion
using EpiTectH Plus DNA Bisulfite kit (QIAGEN) following the
supplied protocols. Primers for PCR amplification of the converted
DNA were designed using EpiDesignerH software (Sequenom, San
Diego, CA, USA). Two overlapping amplicons were analyzed in
the promoter region of each genomic locus (miR-200b-a-429 and
miR-200c-141). Primer sequences are shown in Table S2.
Amplicons were analyzed using the MassARRAY MALDI-TOF
mass spectrometry platform (Sequenom). Data were analyzed
using EpiTyper software (Sequenom) and the methylation level of
the promoter sequences was calculated by averaging the methyl-
ation level of the individual CpG units.
Statistical Analysis
Statistical significance of relative changes in miRNA and
mRNA expression between different groups of breast tumors
was determined by the Wilcoxon rank-sum test, correcting p-
values with the Benjamini-Hochberg algorithm (p,0.05). A
moderate t-test was used when analyzing statistical differences in
cell line expression data. These analyses were conducted on
Integromics RealTime StatMinerTM 4.2 package (Integromics
S.L., Granada, Spain). SPSS (SPSS inc., Chicago, IL) and JMP
statistical software (SAS Institute Inc., Cary, NC, US) were used to
perform the correlation analyses. Correlation of the normalized
expression data and %CpG methylation data was determined
using the Pearson coefficient.
Results and Discussion
miR-200f Expression Decreases in Breast Tumors with
EMT Features
We investigated miR-200f expression pattern in 70 human
breast cancers comprising ER+, HER2+, and TN tumor subtypes,
including a subset of MBCs with sarcomatous (homologous or
heterologous) differentiation (Figure 1A). No MBCs with
squamous differentiation were included. We found a significant
decrease of all miR-200f members in MBCs compared to the rest
of tumor types. Consistent with this, basal B breast cancer cell
lines, which have been proposed to represent in vitro models of
MBC and claudin-low tumors [5], exhibited significantly reduced
levels of miR-200f expression compared to luminal cell lines
(Figure S1). Moreover, compared with ER+ breast tumors, TN
cancers also exhibited decreased expression of the whole mir-200f,
while HER2+ cancers only showed significant downregulation of
miR-200a and miR-141 (Figure 1A). Hence, miR-200f expres-
sion was higher in ER+ tumors, whereas TN and HER2+ tumors
exhibited intermediate levels, and MBCs showed strong reduction
of miR-200f compared with the rest of groups. Reduced levels of
miR-200f in MBCs and claudin-low tumors relative to other
tumor phenotypes has been previously reported, but detailed
analysis of miR-200f in a variety of human breast cancer
phenotypes were not carried out in these studies [39,40].
Bockmeyer et al [41] analyzed miRNA expression in a profiling
experiment comparing luminal A, luminal B, basal-like and
malignant myoepithelioma, and observed low level miR-200c and
mir-429 expression restricted to malignant myoepithelioma.
However, our larger series of distinct breast cancer phenotypes
allowed us to detect a significant reduction in all miR-200f
members in TN tumors, in addition to the marked reduction
observed in MBCs. As expected, by immunohistochemical analysis
we observed that TN and MBC tumors were positively associated
to the mesenchymal marker vimentin, and ER+ tumors were
associated to the epithelial marker E-cadherin (Figure S2).
Therefore, given that basal-like tumors are suggested to be
particularly prone to acquire EMT-like characteristics [17] and
MBCs are considered as examples of complete EMT [9,10,11],
our data indicate that the expression of miR-200f could be an ideal
Figure 2. Analysis of DNA methylation status of miR-200f promoter sequences in breast tumors. (A) Schematic depiction of miR-200b-a-
429 and miR-200c-141 genomic loci showing CpG islands (green), putative transcription start sites (TSS) and miRNA stem-loop sequences (red). The
regions analyzed for DNA methylation (MassArray) are indicated by a black bar. Chromosomal location is indicated between brackets. (B) The DNA
methylation levels across the regions shown in panel (A) were quantified in breast cancers by Sequenom MassArrayH MALDI-TOF platform. The mean
percentage of methylation levels in three tumor types (ER+, TN, MBC) are represented as box-plots. Statistical significance was determined by
Student’s t test. (C) Expression and %CpG methylation data are represented on a scatter plot matrix showing correlation between the indicated
variables, a 95% bivariate normal density ellipse is imposed on each scatterplot. Pearson correlation coefficients (R) and significance probabilities (P)
are shown. Statistically significant p values (,0.05) are highlighted in red.
doi:10.1371/journal.pone.0047709.g002
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biomarker to assess the degree of occurrence of EMT in breast
cancer.
In order to assess further the association between miR-200f and
EMT transcriptional regulation in breast cancer we analyzed the
expression of diverse EMT-transcriptional inducers including
ZEB1 and ZEB2, which have been reported to directly inhibit
transcriptional activation of miR-200f expression through con-
served E-box elements [27,28]. We found a strong and significant
increase in the expression of SNAI1 and SNAI2 and a moderate but
not statistically significant increase of ZEB1 and ZEB2 in MBCs
compared with the rest of tumor types (Figure 1B). There were
no additional differences in the rest of tumor groups for any of the
analyzed genes. In agreement with our observations in tumor
samples, we detected higher levels of EMT-transcriptional
inducers in basal B cell lines, which exhibited upregulation of
SNAI2, ZEB1 and ZEB2 (Figure S1). These results indicate that
EMT-transcriptional inducers could account for mir-200f down-
regulation in our tumor series. Accordingly, we observed
significant negative correlations between SNAI1/SNAI2 (but not
ZEB1 or ZEB2) and all miR-200f members’ expression levels in
our tumor series (Figure 1C and Figure S3). Since SNAI1/SNAI2
are E-cadherin repressors affecting promoter transcriptional activity
through binding to E-box elements, it is conceivable that these
EMT-transcriptional inducers could affect transcriptional activa-
tion of miR-200f through the conserved E-box elements that have
been functionally defined in previous studies [27,42]. Consistent
with this idea, we demonstrated that overexpression of SNAI2 in
MDCK cells had a strong repressive effect in the transcriptional
activation of miR-200b-a-429 promoter, and this effect was strictly
dependent on E-box motifs (Figure S4). This observation
supports the notion that other EMT-transcriptional inducers,
distinct from ZEB1 and ZEB2, could directly regulate miR-200f
expression. In fact, during the preparation of this manuscript
a study has been published describing a mutually inhibitory
regulatory loop for SNAI2 and miR-200b/miR-1 in a murine
model of aggressive prostate cancer. Transcriptional repression of
miR-200b-a-429 and miR-1 by SNAI2 occurs by direct interaction
through E-box elements; and conversely, SNAI2 was functionally
validated as target gene for miR-1 and miR-200b [43]. As miR-1
and miR-200 target sequences identified in SNAI2 39-UTR are well
conserved, mutually repressive regulation for SNAI2 and miR-1/
miR-200b-a-429 is likely to be a common regulatory mechanism
operating in human and other species. SNAI2 has been described
as the EMT-transcriptional inducer responsible for conferring
a basal-like phenotype in breast cancer [44,45], so it would be
possible that this new regulatory axis plays an important
contribution to the EMT-like features observed in these tumors.
Hypermethylation of miR-200c-141 Promoter Sequences
in MBCs
We next studied the possible mechanisms by which miR-200f
expression could be regulated in the different breast cancer
subtypes. Previous studies have shown that mir-200f is subjected to
epigenetic regulation in cancer and normal tissues
[32,33,34,35,36,42]. The promoter sequences driving transcrip-
tional activation of both miR-200f clusters are located within CpG
islands, and DNA methylation in these CpG islands is associated
to inactivation of miR-200f in cancer [46]. We therefore evaluated
the CpG methylation rates of the respective miR-200f promoter
regions in our tumor series using the Sequenom MassArrayH
MALDI-TOF platform. The promoter sequences analyzed for
miR-200b-a-429 cluster span 415 bp encompassing the transcrip-
tion start site (TSS) functionally defined by Bracken and colleagues
[27]. For miR-200c-141 cluster we studied a region of 426 bp
surrounding the TSS that has also been previously determined
[42] (Figure 2A).
For these analyses we focused our study in ER+, TN and MBC
tumors and observed that DNA methylation levels of miR-200c-
141 locus were significantly higher in MBCs compared with either
ER+ or TN tumors (Figure 2B). Although the methylation levels
of miR-200b-a-429 locus were slightly increased in MBCs, there
were no significant differences among the different tumor types.
Interestingly, the expression of miR-200c-141 and its DNA
methylation levels showed a significant inverse correlation in
breast tumors, but no such association was observed for miR-200b-
a-429 cluster (Figure 2C). In agreement with these data in breast
tumors, basal B cancer cell lines also exhibited elevated DNA
methylation rates at miR-200c-141 promoter, reaching levels
.80%, as observed in MBCs. Additionally, we also detected
elevated methylation at miR-200b-a-429 locus in basal B cell lines
(.50%), that correlates with downregulation of miR-200b, miR-
200a and miR-429 (Figures S5 and S1). Taken together, these
results indicate that DNA methylation is a major epigenetic
mechanism regulating transcriptional activation of miR-200c-141
cluster in MBCs/basal B cancer cells and suggest that this
epigenetic event is associated with the acquisition of EMT features
in these tumors.
A recent study [47] has functionally defined an independent
promoter region for miR-200b-a-429 cluster, capable of directing
transcriptional activity at the same level as the promoter sequences
formerly described [27] and studied here. Remarkably, the two
promoter sequences were differentially methylated in breast
cancer clinical specimens suggesting different regulatory roles
[47]. Similarly, Vrba et al [33] described that normal human
mammary cells exhibit differential methylation of the proximal
and distal parts of the CpG island (Figure 2A), where the
respective miR-200b-a-429 promoter regions are located. Wee et al
[47] have also shown that methylation of both promoter regions is
inversely associated with miR-200b expression levels in breast
cancer cell lines as well as in clinical specimens. However, we did
not observe such correlation in our tumor series for the analyzed
promoter region (Figure 2C). This discrepancy could be due to
differences in sample size. The authors also reported that
hypermethylation of the newly identified promoter, but not of
the formerly defined one, was associated with loss of ER+ or PR+
expression, and gain of HER2+ phenotype. In agreement with this
we did not observe differences in DNA methylation levels of the
former promoter region in TN or MBCs (which lack expression of
ER and PR), compared with ER+ tumors (Figure 2B).
It has recently been reported that the two clusters comprising
the miR-200f display different but complementary epigenetic
Figure 3. miR-200f and EMT-transcriptional inducers are modulated during in vitro EMT in breast basal cell lines. Expression of (A)
miR-200f and (B) EMT-transcriptional inducers was evaluated by qRT-PCR in the sorted epithelial (EpCAM+) and mesenchymal (Fibros)
subpopulations within MCF12A and Myo1089 cell lines. Data are normalized to the expression of RNU48 and 18S respectively. Bars represent mean
expression changes6SE in Fibros subpopulation relative to EpCAM+ cells (baseline). Three biological replicates were measured. Moderated t-test was
performed to evaluate statistical significance (p,0.001 for all miRNAs analyzed in panel A. NS, non significant). (C) Methylation status of miR-200f
promoter sequences in EpCAM+ and Fibros subpopulations within MCF12A and Myo1089 cell lines. Histogram bars represent averaged methylation
levels (6SE) for the promoter sequences of miR-200f loci. Statistically significant differences are indicated (*p,0.001, Student’s t-test).
doi:10.1371/journal.pone.0047709.g003
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mechanisms to regulate their expression in human mammary cells
[33]. The authors describe that miR-200b-a-429 cluster is
epigenetically repressed in mammary fibroblasts by the repressive
histone mark H3K27me3, while DNA methylation is the major
epigenetic mechanism repressing the transcriptional activation of
miR-200c-141 cluster. Our results are in accordance with these
observations, since we only observed expression/DNA methyla-
tion correlation for miR-200c-141 cluster (Figure 2C). Neverthe-
less, it would be necessary to determine other epigenetic marks in
order to establish the actual epigenetic state of miR-200f loci.
Indeed, in hepatocellular carcinoma, miR-200b-a-429 promoter
sequences show decreased histone H3 acetylation, a permissive
epigenetic mark that is in turn modulated by miR-200a through
direct targeting of the histone deacetylase 4 (HDAC4) [48].
Spontaneous EMT in Normal Basal Breast Cell Lines is
Associated to Hypermethylation of miR-200c-141 Locus
To study further the association between modulation of miR-
200f and induction of EMT in breast cancer and to validate the
epigenetic regulation of miR200 during this process, we utilized
our recently described model systems for spontaneous EMT in
mammary cells [38]. We have demonstrated that the immortalized
non-tumorigenic cell lines MCF12A and Myo1089 contain two
functionally and phenotypically distinct subpopulations: EpCAM-
pos/CD49fhigh cells (referred as to ‘EpCAM+’) show the typical
cobblestone epithelial morphology and phenotypically resemble
basal A breast cancers, while EpCAMneg/CD49fmed/low cells
(‘Fibros’) show fibroblast-like spindle morphology and exhibit
a gene expression pattern resembling stromal fibroblast and Basal-
B/claudin-low cancers [38]. Importantly, the Fibros subpopula-
tion arises from EpCAM+ cells through an EMT-like process.
Here, we sorted these two subpopulations from MCF12A and
Myo1089 cells and studied the expression of the miR-200f
members and their DNA methylation status as well as expression
of EMT-transcriptional inducers. As expected, the expression
levels of all of miR-200f members showed a significant decrease in
Fibros compared to EpCAM+ subpopulation in both cell lines
(Figure 3A). Moreover, downregulation of miR-200f in the Fibros
subpopulation is accompanied by an increase in the expression
levels of ZEB1 and ZEB2 (Figure 3B and [38]), while differential
expression of SNAI1 and SNAI2 was only observed in MCF12A
and Myo1089 cell lines, respectively. Importantly, Fibros sub-
population from Myo1089 cells showed increased methylation
level of miR-200c-141 locus but not of miR-200b-a-429 locus
(Figure 3C), which parallels the result observed in MBCs
(Figure 2B). No differential DNA methylation levels were found
in the MCF12A cell line, but this could be due to the fact that
EMT in this cell line is more transient than in Myo1089 cells [38].
Overall, these data reproduced what we observed in MBCs, which
exhibited strong reduction of miR-200f with hypermethylation at
miR-200c-141 locus, and increased levels of EMT-transcriptional
inducers.
Conclusion
We have observed that TN and specially MBCs breast cancers
exhibit lower level expression of miR-200f compared to ER+
tumors. Using an in vitro model of EMT and the analysis in
human breast cancer samples we have shown that the strong
decrease of miR-200f expression levels is accompanied by
upregulation of EMT-transcriptional inducers and hypermethyla-
tion of miR-200c-141 locus, thus supporting the functional
association between EMT and miR-200f regulation in breast
cancer. Therefore, our data indicate that expression and
methylation status of miR-200f could be used as a hypothetical
biomarker to assess the occurrence of EMT in breast cancer both
in vitro and in vivo.
Supporting Information
Figure S1 Expression levels of miR-200f and EMT-
transcriptional inducers measured by qRT-PCR in
breast cancer cell lines. (A) Strong downregulation of miR-
200f is observed in mesenchymal-like basal B cell lines (MDA-MB-
231, BT-549) compared with luminal (MCF7, T47D) and HER2+
(SKBR3, BT474) cell lines. Expression levels are normalized to
RNU48. (B) Basal B cell lines (MDA-MB-231, BT-549) exhibit
higher expression of SNAI2, ZEB1 and ZEB2 genes than luminal
and HER2+ breast cancer cells. Expression levels are normalized
to 18S.
(PDF)
Figure S2 Immunohistochemistry for E-cadherin and
Vimentin. (A) Representative IHC pictures for E-cadherin and
Vimentin expression in ER+ and MBC tumors. (B) Scoring data
for IHC are expressed as percentage. The scoring criteria for
immunohistochemical staining according to the threshold of
positive staining for each marker was as follows: E-cadherin,
absent : no expression, reduced: less than 50% of epithelial cells
with complete and intense membrane expression, conserved 50%
or more epithelial cells with complete and intense membrane
expression; vimentin positive .10% of positive epithelial cells.
(PDF)
Figure S3 Correlations on expression levels of miR-200f
members and EMT-transcriptional inducers in breast
tumors. Data shown are an extension from those in Figure 1.
Pearson correlation coefficients (R) and significance probabilities
(P) for each gene pair are shown. Darker shading indicates
significant correlations.
(PDF)
Figure S4 Stable overexpression of SNAI2 represses
transcriptional activation of miR-200b-a-429 promoter
through E-box elements. MDCK-CMV (control) and
MDCK-SNAI2 cell lines were transfected with firefly luciferase
reporter constructs containing the promoter sequences of mouse
E-cadherin (2178/+92) or human miR-200b-a-429 (2321/+120).
Constructs containing the WT promoter sequences or mutated E-
box elements were utilized. Relative luciferase activity of the WT
constructs was set to 1. A strong de-repressive effect was observed
for miR-200b-a-429 E1E2 mutant promoter in the cell line
overexpressing SNAI2. Bars represent mean fold change in relative
luciferase activity 6 SE in three independent experiments.
(PDF)
Figure S5 DNA methylation status of miR-200f loci in
breast cancer cell lines. Basal B cell lines (MDA-MB-231, BT-
549) show higher methylation rates than luminal (MCF7, T47D)
and HER2+ (SKBR3, BT474) cell lines in both miR-200f loci.
(PDF)
Table S1 Clinical characteristics of the tumor series.
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Table S2 Primers used for DNA methylation analysis.
(PDF)
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